Administration of atrial natriuretic peptide attenuates reperfusion phenomena and preserves left ventricular regional wall motion after direct coronary angioplasty for acute myocardial infarction

Circulation Journal

Volumn 67, Issue 5, 2003, Pages 443-448

  Kuga, Hideyo ^a   Ogawa, Kenichi ^a   Oida, Akitugu ^a   Taguchi, Isao ^a   Nakatsugawa, Masatoshi ^a   Hoshi, Toshiyasu ^a   Sugimura, Hiroyasu ^a   Abe, Shichirou ^a   Kaneko, Noboru ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Intracoronary administration; Left ventricular ejection fraction; Left ventricular end diastolic volume index; Persistent ST segment elevation; Ventricular tachycardia

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CARPELITIDE; RECOMBINANT HUMAN ATRIAL NATRIURETIC PEPTIDE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY DILATATION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL MOTION; HEART MUSCLE REPERFUSION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE REMODELING; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRACORONARY INFUSION; MALE; REPERFUSION INJURY; ST SEGMENT ELEVATION;

EID: 0037995741     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.67.443     Document Type: Article

References (44)

1. Gruppo Italiano per lo Studiomella Strptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
2. Gersh BJ. Optimal management of acute myocardial infarction at the dawn of the next millennium. Am Heart J 1999; 138: S188-S202.
3. Matsumura, K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97: 795-804.
4. Neumann F, Ott I, Gawaz M, Richardt G, Holtzapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92: 748-755.
5. Cronstein BN, Levin RI, Belanoff J, Weissman G, Hirshhom R. Adenosine: Endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986; 78: 760-770.
6. Wu KC, Kim RJ, Bluemke DA, Rochitte CE, Zerhouni EA, Bechker LC, et al. Quantification and time course of microvascular obstraction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion. J Am Coll Cardiol 1998; 33: 1756-1764.
7. Serebruany V, Schlossberg ML, Edenbaum LR, Herzog WR, Gurbel PA. Serial changes of soluble endothelin-1 levels during myocardial ischemia-reperfusion: Effects of magnesium, diltiazem and a novel MAC-1 inhibitor. Pharmacol Res 1998; 38: 165-172.
8. Davies SW, Ranjadayalan K, Wickens DG, Dormandy TI, Umachandran V, Timmis AD. Free radical activity and left ventricular function after thrombolysis for acute infarction. Br Heart J 1993; 69: 114-120.
9. Du Toit EF, Opie LH. Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion. Circ Res 1992; 70: 960-967.
10. Antman EM. Magnesium in acute myocardial infarction: Overview of available evidence. Am Heart J 1996; 132: 487-494.
11. Theroux P, Gregoire J, Chin C, Pelletier G, de Guise P, Juneau M. Intravenous diltiazem in acute myocardial infarction-Diltiazem as adjunctive therapy to activase (DATA) trial. J Am Coll Cardiol 1998; 32: 620-628.
12. Taniyama Y, Ito H, Iwakura K, Masuyama T, Hori M, Takiuchi S, et al. Beneficial effect of intracoronary verapamil on microvascular and myocardial salvage in patients with acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1193-1199.
13. Ito H, Taniyama Y, Iwakura K, Nishikawa N, Masuyama T, Kuzuya T, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33: 654-660.
14. Nagao K, Hayashi N, Kanmatsuse K, Kikuchi S, Ohuba T, Takahashi H. An early and compete reperfusion strategy for acute myocardial infarction using fibrinolysis and subsequent transluminal therapy: The FAST trial. Circ J 2002; 66: 576-582.
15. Yasuda T, Hashimura K, Matsu-ura Y, Kato Y, Ueda T, Mori I, et al. Nicorandil, a hybrid between nitrate and ATP-sensitive potassium channel opener, preconditions human heart to ischemia during percutaneous transluminal coronary angioplasty. Jpn Circ J 2001; 65: 526-530.
16. Dairaku Y, Miura T, Harada N, Kimura M, Okamura T, Iwamoto H, et al. Effect of ischemic preconditioning and mitochondrial KATP channel openers on chronic left ventricular remodeling in the ischemic-reperfused rat heart. Circ J 2002; 66: 411-415.
17. Wu DJ, Minatoguchi S, Uno Y, Arai M, Nishida Y, Hashimoto K, et al. Combination of N-methyl-1-deoxynojirimaycin and ischemic preconditioning markedly reduces the size of myocardial infarcts in rabbits. Jpn Circ J 2001; 65: 673-677.
18. Takata Y, Hirayama Y, Kiyomi S, Ogawa T, Iga K, Ishii T, et al. The beneficial effects of atrial natriuretic peptide on arrythmias and myocardial high-energy phosphates after reperfusion. Cardiovasc Res 1996; 32: 286-293.
19. Abramson BL, Ando S, Notarius CF, Rongen GA, Floras JS. Effect of atrial natriuretic peptide on muscle symapathetic activity and its reflex control in human heart failure. Circulation 1999; 99: 1810-1815.
20. Laragh JH. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis. N Engl J Med 1985; 313: 1330-1340.
21. Herrmann HC, Rosenhtal AD, Davis CA. Cardiovascular effects of intracoronary atrial natriuretic peptide administration in man. Am Heart J 1990; 120: 308-315.
22. Matsumura T, Kugiyama K, Sugiyama S, Ohgushi M, Yamada K, Suzuki M, et al. Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophil-induced endothelial cytotoxity. J Clin Invest 1996; 97: 2192-2203.
23. Kohno M, Yasunari K, Yokokawa K, Murakawa K, Horio T, Takeda T, et al. Inhibition by atrial and brain natriuretic peptides of endothelin-I secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 1991; 87: 1999-2004.
24. Pella R. The protective effect of natriuretic peptide (ANP) on cells damaged by oxygen radicals is mediated through elevated CGMP-levels, reduction of calcium-inflow and probably G-proteins. Biochem Biophys Res Commun 1991; 174: 549-555.
25. Gorbig MN, Gines P, Bataller R, Nicolas JM, Garcia-Ramallo E, Tobias E, et al. Atrial natriuretic peptide antagonizes endothelin-induced calcium increase in cell contraction in cultured human hepatic stellate cells. Hepatology 1999; 30: 501-509.
26. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutsui T, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with anterior acute myocardial infarction. J Am Coll Cardiol 2000; 35(Suppl A): 345A.
27. Tamamori M, Ito H, Hiroe M, Marumo F, Hata R. Stimulation of collagen sythesis in rat cardiac fibroblasts by exposure to hypoxic culture conditions and suppression of the effect by natriuretic peptides. Cell Biol Int 1997; 21: 175-180.
28. Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata M, Lin M, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-I gene expression. J Clin Invest 1995; 96: 1059-1065.
29. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit: A two year experience with 250 patients. Am J Cardiol 1967; 20: 457-464.
30. Nakagawa Y, Ito H, Kitakaze M, Kusuoka H, Hori M, Kuzuya T, et al. Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: Retrospective clinical evidence of 'Preconditioning'. J Am Coll Cardiol 1995; 25: 1076-1083.
31. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial. Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-154.
32. Gorgels AP, Vos MA, Letsch IS, Vershuuren EA, Bär FW, Janssen JHA, et al. Usefulness of the accelerated idioventricular rhythm as a marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1988; 61: 231-235.
33. Goldberg S, Greenspon AJ, Urban PL, Muza B, Berger B, Walinsky P, et al. Reperfusion arrhythmia: A marker of reperfusion of antegrade flow during intracoronary thrombolysis for acute myocardial infarction. Am Heart J 1983; 105: 26-32.
34. Claeys MJ, Bosmans J, Veenstra L, Jorens P, De Raedt H, Vrints CJ. Determinants and prognostic implications of persistent ST-segment elevation after primary angioplasty for acute myocardial infarction. Circulation 1999; 99: 1972-1977.
35. Greene DG, Carlisle R, Grant C, Bunnell IL. Estimation of left ventricular volume by one-plane cineangiography. Circulation 1967; 35: 61-69.
36. Sheehan FH, Stewart DK, Dodge HT, Mitten S, Bolson EL, Brown BG. Variability in the measurement of regional left ventricular wall motion from contrast angiograms. Circulation 1983; 68: 550-559.
37. Warren SE, Bhargva V, Vieweg WVR, Dennish GW, Alpert JS, Hagen AD. Semiautomated method for evaluation of left ventricular regional wall motion in coronary artery disease. Am J Cardiol 1980; 46: 832-836.
38. Wehrens XHT, Doevendans PA, Oude Ophuis TJ, Wellens HJJ. A comparison of electrocardiographic changes during reperfusion of acute myocardial infarction by thrombolysis or percutaneous transluminal coronary angioplasty. Am Heart J 2000; 139: 430-436.
39. Villanueva FS, Glasheen WP, Skeienar J, Kaul S. Characterization of spatial patterns of flow within the reperfused myocardium by myocardial contrast echocardiography: Implication in determining extent of myocardial salvage. Circulation 1993; 88: 2596-2906.
40. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990; 81: 1161-1172.
41. Dubois-Rande JL, Adnot S, Benvenuti C, Merlet P, Hittinger L, Sadiame S, et al. Hemodynamic response to intracoronary infusion of atrial natriuretic factor in patients with normal or altered left ventricular function. J Cardiovasc Pharmacol. 1991; 17: 608-614.
42. Kai H, Egashira K, Hirooka Y, Sugimachi M, Suzuki S, Kuga T, et al. Effects of intracoronary infusion of atrial natriuretic peptide on pacing-induced myocardial ischemis in patients with effort angina pectoris. Coronary Artery Dis 1994; 5: 987-994.
43. Kugiyama K, Ohgushi M, Sugiyama S, Motoyama T, Kawano H, Hirashima O, et al. Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic coronary arteries in coronary spastic angina. Am J Cardiol 1997; 79: 606-610.
44. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Cardiol 1985; 5: 587-592.